March 4, 2020 / 12:42 PM / a month ago

BRIEF-Alkermes Says Phase 3 Study Of Schizophrenia Drug Published In Medical Journal

March 4 (Reuters) - Alkermes Plc:

* JOURNAL OF CLINICAL PSYCHIATRY PUBLISHES DATA FROM ALKERMES’ PHASE 3 ENLIGHTEN-1 EFFICACY STUDY OF ALKS 3831 IN PATIENTS WITH SCHIZOPHRENIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below